Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study.

ABSTRACT:

Background

In this study, the efficacy of an IL-6 antagonist, Tocilizumab, administered in the early period was studied in intensive care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation not receiving mechanical ventilation support.

Methods

Patients with COVID-19 pneumonia who have signs of hypoxia and systemic inflammation and/or who have acute bilateral infiltrates on chest radiograph and who received tocilizumab treatment were compared with the patients who received standard medical therapy. Patients who were followed up with COVID-19 pneumonia and respiratory failure between March 2020 and March 2021 were retrospectively evaluated in the study. A 400 mg - 800 mg iv dose (depending on weight) of Tocilizumab was administered. The primary endpo

SUBMITTER: Kucuk MP 

PROVIDER: S-EPMC10734863 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature